自体造血干细胞移植治疗淋巴瘤56例疗效分析

Clinical efficacy analysis of autologous hematopietic stem cell transplantation in 56 patients with lymphoma

目的探讨自体造血干细胞移植治疗淋巴瘤的临床疗效及安全性。方法回顾性分析2004年1月至2014年12月自体造血干细胞移植治疗淋巴瘤56例及随访结果。结果随访中位时间49个月。目前存活22例。余34例死亡原因分别为:复发28例,单次移植者24例,双次移植者4例;移植相关死亡6例,单次移植者3例,双次移植者3例。结论自体造血干细胞移植可以改善淋巴瘤患者尤其是恶性程度较高患者的预后;双次自体造血干细胞移植复发率低于单次移植,可能会增加移植相关死亡。

Objective To investigate the clinical efficacy and safety of autologous hematopoietic stem cell transplantation （AHSCT） in the treatment of lymphoma. Methods Retrospectively analyzed follow - up results of 56 patients with lymphoma who have received AHSCT in our hosipital from January 2004 to December 2014. Results The median follow - up time is 49 months, 22 patrents survived and 34 cases died. The cause of death were as follows ： 28 cases of recurrence, a single transplant in 24 cases, 4 cases double transplant; 6 cases of transplant - related deaths, a single transplant three cases, two - time transplant three cases. Conclusion AHSCT can improve the prognosis of patients with lymphoma, especially in patients with a high degree of malignancy. The recurrence rate of DAHSCT is lower than SAH-SCT, DAHSCT may increase transplant - related deaths.